gefitinib has been researched along with thyroxine in 4 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (thyroxine) | Trials (thyroxine) | Recent Studies (post-2010) (thyroxine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 38,989 | 1,410 | 6,550 |
| Protein | Taxonomy | gefitinib (IC50) | thyroxine (IC50) |
|---|---|---|---|
| Transthyretin | Homo sapiens (human) | 2.1939 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 5.25 | |
| Solute carrier organic anion transporter family member 4C1 | Homo sapiens (human) | 8 | |
| Bile acid receptor | Homo sapiens (human) | 7.86 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chang, TC; Changou, CA; Chen, YR; Chin, YT; Davis, PJ; Liao, YM; Lin, HY; Nana, AW; Shih, A; Shih, YJ; Stain, SC; Wang, K; Wang, LS; Wang, SH; Whang-Peng, J; Wu, CH; Yang, YS | 1 |
| Chang, TC; Chang, WJ; Changou, CA; Chen, YR; Cheng, RH; Chin, YT; Chiu, SJ; Chu, HR; Davis, PJ; Hastuti, ED; Huang, TY; Li, ZL; Lin, HY; Liu, FC; Mousa, SA; Pan, YS; Shih, YJ; Wang, K; Wang, SH; Whang-Peng, J; Wu, A | 1 |
1 review(s) available for gefitinib and thyroxine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for gefitinib and thyroxine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Enzyme Activation; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Polyglactin 910; Thyroxine; Xenograft Model Antitumor Assays | 2018 |
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polyglactin 910; Thyroxine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |